Andrew Owen is Professor of Molecular and Clinical Pharmacology at the University of Liverpool, UK. He is also affiliated to the MRC Centre for Drug Safety Science and the Wolfson Centre for Personalised Medicine. He is Chair of the British Society for Nanomedicine, a fellow of the Royal Society of Biology, a fellow of the British Pharmacological Society and a member of the steering committee for the APS Nanomedicines Focus Group. His clinical and basic research focuses on understanding mechanisms that underpin inter-patient variability in pharmacokinetics and pharmacodynamics. In recent years a major emphasis has been to employ knowledge of these mechanisms to accelerate the translation of nanomedicine candidates to clinical applications. Work is supported by the US Agency for International Development, US National Institutes for Health, UK Medical Research Council, European Commission, and UK Engineering and Physical Sciences Research Council. Professor Owen also has strong links with the Clinton Health Access Initiative and Medicine Patent Pool. He has published over 140 original publications, is co-inventor of patents relating to the application of nanotechnology to drug delivery and a co-founder of Tandem Nano Ltd. He is a Founder and Editor in Chief for the Journal of Interdisciplinary Nanomedicine.